To the best of our knowledge, we assessed for the first time the impact of KRAS mutations, including distinguished mutation subtypes, on prognosis in Chinese CRC patients when the confounding effect of a BRAF mutation was controlled. The gene discussed is BRAF; the disease is colorectal carcinoma.